Pilatus Biosciences Receives FDA Clearance for First-in-Class Anti-CD36 Metabolic Checkpoint Antibody PLT012
核心洞察
Pilatus Biosciences (搜索) announced FDA clearance of its IND application for PLT012, a first-in-class anti-CD36 (搜索) monoclonal antibody targeting metabolic dysfunction in solid tumors (搜索).
PLT012 represents the first metabolic checkpoint therapy designed to reprogram the tumor microenvironment by blocking CD36 (搜索)-mediated lipid uptake and immune suppression.
The Phase 1 clinical trial is expected to begin in the first quarter of 2026, evaluating safety, tolerability, and preliminary efficacy in solid tumor patients.
Pilatus Biosciences (搜索) Inc. has received FDA clearance for its Investigational New Drug (IND) application for PLT012, marking a significant milestone for the first-in-class anti-CD36 (搜索) monoclonal antibody designed to treat solid tumors (搜索) through metabolic checkpoint inhibition. The biopharmaceutical company plans to initiate a Phase 1 clinical trial in the first quarter of 2026.
Novel Metabolic Checkpoint Mechanism
PLT012 represents a fundamentally new therapeutic approach that targets CD36 (搜索), an immunometabolic regulator highly expressed on exhausted T cells, regulatory T cells, and tumor-associated macrophages while being far less prevalent in healthy tissues. The antibody is engineered to block CD36-mediated lipid uptake and immune suppression within the tumor microenvironment.
"PLT012 represents a fundamentally new approach to treating solid tumors (搜索) by addressing the metabolic dysfunction that underlies immune exhaustion," said Raven Lin, Ph.D., Co-Founder and CEO of Pilatus Biosciences (搜索). "Leveraging our deep expertise in metabolic immunology, PLT012 was developed to simultaneously enhance effector T cell function and suppress tumor-promoting immune populations, while maintaining a favorable safety profile."
The therapy's dual-action mechanism is designed to restore metabolic fitness in cytotoxic T cells while reducing immunosuppressive cell populations, ultimately promoting stronger anti-tumor immune responses.
Preclinical Efficacy and Combination Potential
In preclinical models, PLT012 demonstrated monotherapy activity across both immune-hot and immune-cold tumors. The antibody showed potential synergy with PD-1 (搜索)/PD-L1 (搜索) inhibitors, supporting its development as both a single agent and combination therapy. Preclinical studies revealed that PLT012 can overcome immunogenically cold environments and elicit strong anticancer effects.
"Targeting CD36 (搜索) represents a promising new way to reshape the tumor microenvironment," said Anthony El-Khoueiry, M.D., the trial's lead principal investigator and Verna R. Richter Chair in Cancer Research at USC Norris Comprehensive Cancer Center (搜索). "PLT012's ability to modulate metabolic dysfunction and reinvigorate exhausted T cells positions it as a potentially important therapeutic option for tumors that do not respond to current immunotherapies."
Clinical Development Strategy
The upcoming Phase 1, first-in-human clinical trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary signs of clinical activity. The study will include expansion cohorts planned for tumor types strongly influenced by CD36 (搜索)-mediated metabolic dysregulation.
Pilatus has also received FDA Orphan Drug Status for PLT012 for the treatment of liver and intrahepatic bile duct cancers, highlighting the therapy's potential in addressing specific unmet medical needs.
Targeting Hepatic Malignancies
The hepatic microenvironment presents particular challenges for immunotherapy due to its tolerogenic and macrophage-rich nature, which can dampen effector T-cell activity and contribute to weaker responses to immunotherapy treatments for hepatocellular carcinoma (搜索) (HCC) and liver metastases.
"The hepatic microenvironment is tolerogenic and macrophage-rich which can dampen effector T-cell activity, contributing to weaker responses to immunotherapy treatments for HCC and liver metastases," said Anthony W. Tolcher, M.D., FRCPC, FACP of New Experimental Therapeutics (NEXT), San Antonio, Texas. "Preclinical data has shown that PLT012 can overcome this immunogenically cold environment and elicit strong anticancer effects, which we hope will be translated into improved patient outcomes in the planned Phase 1 clinical trial."
Company Background
Founded in 2022 from the Ludwig Institute for Cancer Research and supported by the Cancer Research Institute, Pilatus Biosciences (搜索) operates internationally with R&D teams in Switzerland and Taiwan. The company focuses on developing metabolic checkpoint immunotherapies to address unmet medical needs in cancer and immune-related diseases, with PLT012 serving as its lead program targeting CD36 (搜索) to reprogram the tumor microenvironment and restore anti-tumor immunity in solid tumors (搜索).